RT Journal Article
SR Electronic
T1 Characteristics of patients newly prescribed a long acting bronchodilator in the United Kingdom (UK)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1074
VO 44
IS Suppl 58
A1 Sarah Landis
A1 Keele Wurst
A1 Hoa Le
A1 Hana Muellerova
A1 Kourtney Davis
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P1074.abstract
AB Objective: Characterize patients newly prescribed long acting bronchodilator (LABD) monotherapy for maintenance treatment of COPD and assess treatment changes over 24 months.Methods: Retrospective cohort of COPD patients aged ≥40yrs and newly prescribed long acting beta-agonists (LABA) or long acting muscarinic (LAMA) monotherapy between 1/1/2009-30/11/2012 identified from UK Clinical Practice Research Datalink and followed for up to 24 months. New use defined as no LABD or inhaled corticosteroid use in 12 months prior to or at initial prescription. Patient characteristics, treatment patterns, and adherence (medication possession ratio [MPR]) examined during 24 months follow-up.Results: 5,267 COPD patients newly prescribed LAMA (83%) or LABA (17%) monotherapy; mean age 70 years, 56% male. At 24 months, adherence (MPR ≥80%) to initially prescribed therapy was higher for LAMA (43%) compared to LABA (36%).View this table:Treatment pattern over 24 months after LAMA or LABA monotherapyConclusion: In this UK COPD cohort, less than half of patients adhered to LABD monotherapy; many discontinued treatment. At 24 months, one in three patients initally prescribed LAMA added medication, suggesting additional or alternative therapy may be required to achieve optimal disease control in some patients.